Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Thor Medical ASA (TRMED.OL)
NOK4.33
+0.05 (+1.05%)
NO OSL Healthcare Biotechnology
Address
Karenslyst allé 9C 278
Oslo, NO
Oslo, NO
CEO
Jasper Kurth
Website
thormedical.no
IPO
2015-03-23
ISIN NO0010597883
Description
Established in 2017, Thor Medical ASA, with its headquarters in Oslo, Norway, specializes in the development and provision of alpha-particle emitters for oncology treatments within Norway.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
NOK4.33
+0.05 (+1.05%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
-0.27
Float Shares
102.67M
Free Float %
28.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.54% | +3.11% | +4.74% | +8.92% | +3.34% | -7.39% | +90.95% | +572.46% | -80.98% | -81.38% | -86.24% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
4.33
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.99
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+5.6% Q2'25: -72.3% (vs Q2'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-17,525.0%
-
EBIT margin Biotechnology: +0.0%-17,425.0%
-
ROIC Biotechnology: -16.1%-11.5% ★
-
Share dilution Biotechnology: -3.4%+40.8% Q2'25: +0.7% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-6.77×
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 10.0K (-100.0%)
|
—
|
400.0K
est: 3.00M (-86.7%)
|
49.00M
49.00M – 49.00M
+1,533.3% YoY
|
168.00M
168.00M – 168.00M
+242.9% YoY
|
184.00M
184.00M – 184.00M
+9.5% YoY
|
604.00M
604.00M – 604.00M
+228.3% YoY
|
| EBITDA |
-6.83M
|
-41.6K
|
-48.80M
est: 1.80M (-2,811.1%)
|
29.40M
29.40M – 29.40M
+1,533.3% YoY
|
100.80M
100.80M – 100.80M
+242.9% YoY
|
110.40M
110.40M – 110.40M
+9.5% YoY
|
362.40M
362.40M – 362.40M
+228.3% YoY
|
| EBIT |
-7.16M
|
-43.9K
|
-69.70M
est: 1.80M (-3,972.2%)
|
29.40M
29.40M – 29.40M
+1,533.3% YoY
|
100.80M
100.80M – 100.80M
+242.9% YoY
|
110.40M
110.40M – 110.40M
+9.5% YoY
|
362.40M
362.40M – 362.40M
+228.3% YoY
|
| Net Income |
-26.56M
est: -300.95M (+91.2%)
|
-42.21M
est: -113.18M (+62.7%)
|
-58.00M
est: -83.00M (+30.1%)
|
-46.48M
-46.48M – -46.48M
+44.0% YoY
|
-36.52M
-36.52M – -36.52M
+21.4% YoY
|
-23.24M
-23.24M – -23.24M
+36.4% YoY
|
66.40M
66.40M – 66.40M
+385.7% YoY
|
| SGA |
3.14M
|
13.3K
|
49.60M
est: 76.80M (-35.4%)
|
1.25B
1.25B – 1.25B
+1,533.3% YoY
|
4.30B
4.30B – 4.30B
+242.9% YoY
|
4.71B
4.71B – 4.71B
+9.5% YoY
|
15.46B
15.46B – 15.46B
+228.3% YoY
|
| EPS |
-0.03
est: -1.28 (+97.5%)
|
-0.18
est: -0.48 (+62.5%)
|
-0.17
est: -0.25 (+32.0%)
|
-0.14
-0.14 – -0.14
+44.0% YoY
|
-0.11
-0.11 – -0.11
+21.4% YoY
|
-0.07
-0.07 – -0.07
+36.4% YoY
|
0.20
0.20 – 0.20
+385.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Ownership data is not available for this company yet.
Executive team
Top executives
EBIT / Employee
-77.4K
Shares Outstanding
360.00M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jasper Kurth | Chief Executive Officer | 5M | male |
| Brede Ellingsæter | Chief Financial Officer & Chief Operating Officer | 3M | male |
| Astrid Liland | Executive Vice President of HSEQ | 2M | female |
| Sindre Hassfjell | Chief Technology Officer | 2M | male |
| Alf Bjørseth | Executive Vice President of Business Development & Strategic Advisor | 2M | — |
| Mathias Nilsen Reierth | Head of Communications & Corporate Affairs | — | male |
| Therese Kvehaugen | Executive Vice President of Human Resources | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TRMED.OL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
